CAM
BMY icon

Cresset Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Cresset Asset Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25M Buy
412,464
+58,269
+16% +$3.4M 0.11% 127
2025
Q4 		$19.1M Buy
354,195
+22,553
+7% +$1.08M 0.08% 154
2025
Q3 		$15M Buy
331,642
+2,559
+0.8% +$120K 0.07% 181
2025
Q2 		$15.2M Sell
329,083
-106,502
-24% -$5.23M 0.08% 160
2025
Q1 		$26.6M Sell
435,585
-2,943
-0.7% -$172K 0.13% 104
2024
Q4 		$24.8M Sell
438,528
-96,514
-18% -$5.39M 0.12% 108
2024
Q3 		$27.7M Buy
535,042
+97,328
+22% +$4.57M 0.11% 128
2024
Q2 		$18.2M Buy
437,714
+1,301
+0.3% +$58.2K 0.08% 171
2024
Q1 		$23.7M Buy
436,413
+99,360
+29% +$5.06M 0.11% 116
2023
Q4 		$17.3M Sell
337,053
-59,888
-15% -$3.14M 0.1% 135
2023
Q3 		$23M Sell
396,941
-2,019
-0.5% -$124K 0.09% 112
2023
Q2 		$25.5M Buy
398,960
+327,148
+456% +$21.9M 0.03% 149
2023
Q1 		$4.98M Sell
71,812
-298,605
-81% -$21.1M 0.1% 132
2022
Q4 		$25.8M Sell
370,417
-8,952
-2% -$675K 0.33% 43
2022
Q3 		$27M Sell
379,369
-7,482
-2% -$543K 0.34% 35
2022
Q2 		$30M Buy
386,851
+1,195
+0.3% +$91K 0.37% 32
2022
Q1 		$28.4M Sell
385,656
-8,266
-2% -$555K 0.29% 41
2021
Q4 		$24.6M Buy
393,922
+13,464
+4% +$790K 0.24% 47
2021
Q3 		$22.7M Buy
380,458
+3,052
+0.8% +$201K 0.31% 36
2021
Q2 		$25.2M Buy
377,406
+314,093
+496% +$20.5M 0.36% 30
2021
Q1 		$4.03M Sell
63,313
-321,861
-84% -$20M 0.06% 104
2020
Q4 		$24.1M Sell
385,174
-12,583
-3% -$774K 0.39% 26
2020
Q3 		$24M Sell
397,757
-8,463
-2% -$509K 0.45% 25
2020
Q2 		$23.9M Buy
406,220
+5,597
+1% +$335K 0.52% 25
2020
Q1 		$22.3M Buy
400,623
+4,829
+1% +$295K 0.68% 22
2019
Q4 		$27.2M Buy
395,794
+59,404
+18% +$3.4M 0.74% 19
2019
Q3 		$17.1M Buy
336,390
+2,048
+0.6% +$96.3K 0.52% 26
2019
Q2 		$15.2M Buy
334,342
+28,483
+9% +$1.33M 0.47% 27
2019
Q1 		$14.6M Buy
305,859
+17,641
+6% +$879K 0.57% 19
2018
Q4 		$15M Buy
+288,218
New +$15.5M 0.89% 17

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cresset Asset Management's BMY Position: Q1 2026 in Review

Cresset Asset Management increased its Bristol-Myers Squibb (BMY) stake by 16% in Q1 2026, buying an estimated $3.4M and bringing the position to 412,464 shares worth $25M. The position accounts for 0.11% of the portfolio, ranked #127.

Cresset Asset Management first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $30M in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cresset Asset Management held 412,464 shares of Bristol-Myers Squibb worth $25M as of Q1 2026.
  • Cresset Asset Management bought 58,269 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.4M.
  • Bristol-Myers Squibb made up 0.11% of Cresset Asset Management's portfolio in Q1 2026, its #127 holding.
  • Cresset Asset Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
  • Cresset Asset Management's Bristol-Myers Squibb position peaked at $30M in Q2 2022.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.